# Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

> **NCT03496519** · PHASE1 · WITHDRAWN · sponsor: **University of Colorado, Denver**

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** Dose Escalation of Durvalumab and Trabectedin
- **DRUG:** Dose Expansion of Durvalumab and Trabectedin

## Key facts

- **NCT ID:** NCT03496519
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-01
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-10-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Contract Issues
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03496519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03496519, "Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03496519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*